Clinical Trials in the Netherlands / NCT06240559
Recruiting Observational

In Vivo Treatment Verification of Brachytherapy

NCT06240559 · tracked via the Priya Life Science Netherlands tracker
Phase
Observational
Started
2024-02-29
Last updated
2025-05-09

Condition(s) studied

Brachytherapy

Investigational drug(s) / intervention(s)

External imaging panel

External imaging panel: The IP will be placed on the side of the treatment table and will acquire data during the whole treatment, which will be compared against information derived from the treatment plan. The IP based method can detect errors and information about motion and treatment uncertainties that are not currently available.

Study summary

To acquire data during High Dose Rate (HDR) brachytherapy treatments aiming to track the brachytherapy source inside the patient verifying the delivery of the treatment plan.

Medical images (CT,MRI and US) combined with software developed by the investigator will be employed to predict the response of the Investigational product during the treatment and will be used as reference.The IP will be placed on the side of the treatment table and will acquire data during the whole treatment, which will be compared against information derived from the treatment plan. The IP based method can detect errors and information about motion and treatment uncertainties that are not currently available.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Treatment site Gynaecology (Endometrium/Cervix) and prostate * Treatment: HDR Brachytherapy * Patient will be treated on CT Couch * Mentally competent patient Exclusion Criteria: * Incapacitated patient

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Maastro Maastricht Limburg Recruiting

More Maastricht Radiation Oncology trials in the Netherlands

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06240559 on ClinicalTrials.gov ↗ ← All trials in the Netherlands